Alpha Cognition Inc. (NASDAQ:ACOG) Reports Strong Q1 Earnings and ZUNVEYL Market Traction

• Alpha Cognition Inc. (NASDAQ:ACOG) reported strong Q1 earnings, beating consensus estimates with an EPS of -$0.30 and revenue of $3.53 million.
• The company achieved 40% sequential revenue growth, primarily driven by the increasing commercial adoption and market traction of its key product, ZUNVEYL.
• Despite a negative Price-to-Earnings (P/E) ratio of -6.62, indicating unprofitability, Alpha Cognition maintains a robust current ratio of 12.64, showcasing strong short-term financial stability.

Alpha Cognition Inc. (NASDAQ:ACOG) is a biopharmaceutical company focused on treatments for neurological disorders. Its main product is ZUNVEYL, which is notable for being the first new oral Alzheimer's treatment approved in over fifteen years. This positions the company with a unique offering in the market for neurodegenerative diseases.

On May 14, 2026, Alpha Cognition reported its first-quarter earnings. The company posted an earnings per share (EPS) of -$0.30, which was better than the consensus estimate of -$0.41. EPS shows how much profit a company makes for each share of its stock, and a negative number indicates a loss.

The company also announced revenue of $3.53 million, beating the estimated $3.42 million. This represents a significant 40% sequential revenue growth from the fourth quarter of 2025, as highlighted by Businesswire. This growth is driven by the increasing commercial adoption of ZUNVEYL by prescribers and care facilities.

Management noted that March was the strongest month for demand since the product's launch. Approximately 75% of active prescribers are generating repeat prescriptions. This shows both an expanding user base and increasing use among existing prescribers, suggesting strong market traction for the new treatment.

Despite recent revenue growth, Alpha Cognition has a negative Price-to-Earnings (P/E) ratio of -6.62, indicating it is not yet profitable. However, the company shows a strong current ratio of 12.64. This metric suggests Alpha Cognition has a solid ability to cover its short-term financial obligations with its available assets.